Valneva SE (0OB3.L)

Dr. Aseem Malhotra. Political Advisor for many countries including USA. Says no to MRNA Jabs
Dr. Aseem Malhotra. (Courtesy of Dr. Aseem Malhotra)
Vaccines & Safety
Doctor Turns Against Messenger RNA COVID-19 Vaccines, Calls for Global Pause
By Zachary Stieber and Jan Jekielek
September 26, 2022 Updated: September 26, 2022

A doctor who promoted COVID-19 vaccines is now calling for health authorities around the world to pause administration of two of the most-widely utilized COVID-19 vaccines, asserting that the benefits from the vaccines may not outweigh the risks.

“There is more than enough evidence—I would say the evidence is overwhelming—to pause the rollout of the vaccine,” Dr. Aseem Malhotra, a British cardiologist and evidence-based medicine expert, told The Epoch Times.

(VAXX) $2.35 ..Potential BEST Vaccine for Covid Prevention with final Phase 3 results in early Q4 and a Alzheimer Vaccine which is Phase 2b ready = this could be the biggest opp of ALL Covid stocks ...GLTA
"The Phase 3 heterologous boost study evaluating UB-612 against COVID-19 in subjects who have received primary immunization from mRNA, adenovirus vector, or inactivated viral vaccines is ongoing. Vaxxinity expects a topline readout in the second half of 2022, and if successful, these data will support global marketing authorization applications."

###

Wow. Very disappointing. JMHO, the price action since the PFE announcement would have told you that there was a lurking omen . I am actually surprised that this was terminated. My guess is the pivot will be to NVAX in Europe and maybe the rest of the world. I’m still trying to figure out what this means for DVAX.

Regarding Lyme, when there is a bottom in this, VALN will be a good buy. Maybe around 15.

GL

Vaccine will multiply and be fruitful and Valn has other products with revenue increasing exponentially!
Income Statement
Currency in EUR. All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Breakdown
ttm
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Total Revenue
348,085 2021
348,085
110,321
126,196 2020
113,035

THERE is some BS news that VALN said it will not keep producing their EU "Marketing Approved" Covid 19 vaccine???Send us a dose and all of my friends in need will take it!! Safe as can be. ( no side affects?) I recently saw news on about VALN applying for UAL approval in US and other counties in the new future.Why not? haha, they have full marketing approval for Europe and a couple other countries. Cover shorts and go long before the exelent good news!! Covid 19 is not going away with the MRNA vaccines??Thomas Lingelbach, Chief Executive Officer of Valneva, commented, ?We are extremely pleased that the EC granted full marketing authorization for VLA2001, the only inactivated whole-virus COVID-19 vaccine available in Europe. Once again, we have shown that Valneva has the expertise to bring a vaccine all the way from bench to market. Since we began working on VLA2001, we have continued to receive messages from Europeans who are waiting for a more traditional vaccine technology. Now that we have received this full marketing authorization, we hope that the EC and its member states will place orders that reflect this demand. 15% of Europeans over 18 are not yet vaccinated[1], and we believe that making our inactivated vaccine available could increase vaccination coverage and have a meaningful impact on public health.? Couple weeks ago news: Pursuant to an Equity Subscription Agreement, Pfizer has invested #$%$90.5 ($95) million in Valneva, representing 8.1% of Valneva?s share capital at a price of #$%$9.49 per share, through a reserved capital increase. Valneva is planning to use the proceeds to support its contribution to the planned Phase 3 development program for Lyme disease vaccine candidate VLA15. Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022.